Repositorio Dspace

Thrombocytopenic thrombotic purpura related to COVID-19 vaccine: apropos of 4 cases

Mostrar el registro sencillo del ítem

dc.contributor.author Dos Santos, Celia
dc.contributor.author Castera, Santiago
dc.contributor.author Fernández, José
dc.contributor.author Rosales, Julieta Soledad
dc.contributor.author Boughen, Santiago
dc.contributor.author Iastrebner, Marcelo
dc.contributor.author Guerrero, Osvaldo
dc.contributor.author Amell Menco, Carlos
dc.contributor.author Gomez, Mariela
dc.contributor.author González, Jacqueline
dc.contributor.author Alberto, María Fabiana
dc.contributor.author Sánchez Luceros, Analía
dc.date.accessioned 2024-02-27T11:00:49Z
dc.date.available 2024-02-27T11:00:49Z
dc.date.issued 2023-12-30
dc.identifier.citation Dos Santos C, Castera S, Fernandez J, Rosales JS, Crescitelli F, Boughen S, Iastrebner M, Guerrero O, Amell Menco C, Gomez M, Gonzalez J, Alberto MF, Sanchez-Luceros A. Thrombocytopenic thrombotic purpura related to COVID-19 vaccine: apropos of 4 cases. Hematol Transfus Cell Ther. 2023 Dec 30:S2531-1379(23)02605-6. doi: 10.1016/j.htct.2023.11.008. Epub ahead of print. es_ES
dc.identifier.uri https://doi.org/10.1016/j.htct.2023.11.008
dc.identifier.uri https://repositorio.fleni.org.ar/xmlui/handle/123456789/1015
dc.description.abstract The global pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) led to vaccine deployment in record time.1 Very rare cases of thrombotic events associated with thrombocytopenia have only emerged after vaccination of millions of people.2 Acquired Thrombotic Thrombocytopenic Purpura (aTTP) is one of the adverse syndromes that has been progressively reported in the literature. This form of thrombotic microangiopathy (TMA) is associated with presence of autoantibodies against ADAMTS13,3 resulting in formation of platelet thrombi within the microcirculation. Case reports showed that several vaccines against SARS-CoV-2 triggered a de novo or relapse episode of aTTP as summarized by Buetler et al.4 Effective treatment needs to be provided as soon as possible to patients with TTP as it can be a fatal disease. Here, we describe four cases of a newly aTTP diagnosis who had received ChAdOx1 nCov-19, the heterologous recombinant adenovirus combination rAd26 and rAd5 (Gam-COVID-Vac, Sputnik-V) or the inactivated whole virus (BBIBP-CorV, Sinopharm) vaccines. es_ES
dc.language.iso eng es_ES
dc.publisher Elsevier es_ES
dc.rights info:eu-repo/semantics/openAccess
dc.subject COVID-19 es_ES
dc.subject Púrpura Trombocitopénica Trombótica es_ES
dc.subject Purpura, Thrombotic Thrombocytopenic es_ES
dc.title Thrombocytopenic thrombotic purpura related to COVID-19 vaccine: apropos of 4 cases es_ES
dc.type info:eu-repo/semantics/article es_ES
dc.type info:eu-repo/semantics/publishedVersion
dc.description.fil Fil: Rosales, Julieta Soledad. Fleni. Departamento de Neurología. Servicio de Neurología Vascular; Argentina.
dc.description.fil Fil: Fernández, José. Fleni. Departamento de Neurología. Servicio de Neurología Vascular; Argentina.
dc.relation.ispartofPAGINATION S2531-1379(23)02605-6.
dc.relation.ispartofCOUNTRY Brasil
dc.relation.ispartofCITY Río de Janeiro
dc.relation.ispartofTITLE Hematology, transfusion and cell therapy
dc.relation.ispartofISSN 2531-1387
dc.type.snrd info:ar-repo/semantics/artículo es_ES


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Buscar en DSpace


Listar

Mi cuenta

Estadísticas